Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy
Objectives: This paper reports the preclinical evaluation of stable tumor-specific gold nanoparticles (AuNPs) activated by neutron irradiation as a therapeutic option for the treatment of cancers characterized by high tumor angiogenesis. Methods: A selection of promising AuNPs with high avidity to α...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 November 2025
|
| In: |
Pharmaceuticals
Year: 2025, Jahrgang: 18, Heft: 11, Pages: 1-28 |
| ISSN: | 1424-8247 |
| DOI: | 10.3390/ph18111670 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ph18111670 Verlag, kostenfrei, Volltext: https://www.mdpi.com/1424-8247/18/11/1670 
|
| Verfasserangaben: | Güllü Davarci, Carmen Wängler, Klaus Eberhardt, Margaret Tulessin, Christopher Geppert, Ralf Schirrmacher, Gert Fricker, Carolin Mogler, Marc Pretze and Björn Wängler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1950302644 | ||
| 003 | DE-627 | ||
| 005 | 20260129115233.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260127s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ph18111670 |2 doi | |
| 035 | |a (DE-627)1950302644 | ||
| 035 | |a (DE-599)KXP1950302644 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Davarci, Güllü |d 1987- |e VerfasserIn |0 (DE-588)1232736317 |0 (DE-627)1757040641 |4 aut | |
| 245 | 1 | 0 | |a Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy |c Güllü Davarci, Carmen Wängler, Klaus Eberhardt, Margaret Tulessin, Christopher Geppert, Ralf Schirrmacher, Gert Fricker, Carolin Mogler, Marc Pretze and Björn Wängler |
| 246 | 3 | 3 | |a Preclinical evaluation of stable integrin alpha nu beta 3 -specific (198 Au) gold nanoparticles for tumor therapy |
| 264 | 1 | |c 4 November 2025 | |
| 300 | |b Illustrationen, Diagramme | ||
| 300 | |a 28 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Titel sind ny und 3 tiefgestellt, der Ausdruck "198Au" steht in eckiger Klammer, 198 ist dabei hochgestellt | ||
| 500 | |a Gesehen am 27.01.2026 | ||
| 520 | |a Objectives: This paper reports the preclinical evaluation of stable tumor-specific gold nanoparticles (AuNPs) activated by neutron irradiation as a therapeutic option for the treatment of cancers characterized by high tumor angiogenesis. Methods: A selection of promising AuNPs with high avidity to αvβ3-expressing glioma (U-87 MG) cells (IC50 = 82–104 nM) were chosen with different surface loading of Arg-Gly-Asp (RGD) peptides as tumor targeting vectors for integrin αvβ3, a target which is overexpressed in tissues displaying high tumor angiogenesis. Three different [198Au]AuNPs were evaluated applying three injection methods, intravenous (i.v.), intraperitoneal (i.p.), and intratumoral (i.t.), each in a group of six U-87 MG xenograft–bearing mice (54 female athymic nude mice in total). Their biodistribution and tumor accumulation was assessed by in vivo imaging within 1–7 days after injection and 7 days after injection by ex vivo measurement. Results: The developed [198Au]AuNPs exhibited suboptimal biodistribution by i.v. application (accumulation pattern tail > liver > spleen, no significant tumor accumulation) and by i.p. application (accumulation pattern spleen >> liver > pancreas, slight tumor accumulation of <0.3 %ID/g). However, an acceptable biodistribution by i.t. application was observed (5.5 %ID/g in liver, 4.9 %ID/g in spleen, and 3.0 %ID/g in tumor). Conclusions: Despite the very promising in vitro results, the in vivo evaluation suggests that the [198Au]AuNPs represent a platform for the development of restricted therapeutic strategies. | ||
| 650 | 4 | |a 198AuAuNPs | |
| 650 | 4 | |a gold nanoparticles | |
| 650 | 4 | |a radioactive | |
| 650 | 4 | |a RGD peptide | |
| 650 | 4 | |a tumor angiogenesis | |
| 650 | 4 | |a tumor therapy | |
| 700 | 1 | |a Wängler, Carmen |d 1978- |e VerfasserIn |0 (DE-588)133775593 |0 (DE-627)556368177 |0 (DE-576)30009230X |4 aut | |
| 700 | 1 | |a Eberhardt, Klaus |e VerfasserIn |0 (DE-588)1328908844 |0 (DE-627)1888261439 |4 aut | |
| 700 | 1 | |a Tulessin, Margaret |e VerfasserIn |0 (DE-588)1314040383 |0 (DE-627)1876375302 |4 aut | |
| 700 | 1 | |a Geppert, Christopher |d 1973- |e VerfasserIn |0 (DE-588)13089530X |0 (DE-627)507242009 |0 (DE-576)298401223 |4 aut | |
| 700 | 1 | |a Schirrmacher, Ralf |d 1970- |e VerfasserIn |0 (DE-588)121796124 |0 (DE-627)705656918 |0 (DE-576)292889518 |4 aut | |
| 700 | 1 | |a Fricker, Gert |d 1956- |e VerfasserIn |0 (DE-588)1042227675 |0 (DE-627)768469465 |0 (DE-576)393783464 |4 aut | |
| 700 | 1 | |a Mogler, Carolin |d 1980- |e VerfasserIn |0 (DE-588)139825827 |0 (DE-627)613790766 |0 (DE-576)313435995 |4 aut | |
| 700 | 1 | |a Pretze, Marc |d 1983- |e VerfasserIn |0 (DE-588)1054783837 |0 (DE-627)792109120 |0 (DE-576)410510602 |4 aut | |
| 700 | 1 | |a Wängler, Björn |d 1975- |e VerfasserIn |0 (DE-588)129702218 |0 (DE-627)477593909 |0 (DE-576)297793888 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceuticals |d Basel : MDPI, 2004 |g 18(2025), 11, Artikel-ID 1670, Seite 1-28 |h Online-Ressource |w (DE-627)491437528 |w (DE-600)2193542-7 |w (DE-576)281279470 |x 1424-8247 |7 nnas |a Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy |
| 773 | 1 | 8 | |g volume:18 |g year:2025 |g number:11 |g elocationid:1670 |g pages:1-28 |g extent:28 |a Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy |
| 856 | 4 | 0 | |u https://doi.org/10.3390/ph18111670 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.mdpi.com/1424-8247/18/11/1670 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260127 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 129702218 |a Wängler, Björn |m 129702218:Wängler, Björn |d 60000 |d 62900 |e 60000PW129702218 |e 62900PW129702218 |k 0/60000/ |k 1/60000/62900/ |p 10 |y j | ||
| 998 | |g 1054783837 |a Pretze, Marc |m 1054783837:Pretze, Marc |d 60000 |e 60000PP1054783837 |k 0/60000/ |p 9 | ||
| 998 | |g 1042227675 |a Fricker, Gert |m 1042227675:Fricker, Gert |d 160000 |d 160100 |e 160000PF1042227675 |e 160100PF1042227675 |k 0/160000/ |k 1/160000/160100/ |p 7 | ||
| 998 | |g 133775593 |a Wängler, Carmen |m 133775593:Wängler, Carmen |d 60000 |d 62900 |d 60000 |e 60000PW133775593 |e 62900PW133775593 |e 60000PW133775593 |k 0/60000/ |k 1/60000/62900/ |k 0/60000/ |p 2 | ||
| 998 | |g 1232736317 |a Davarci, Güllü |m 1232736317:Davarci, Güllü |d 140000 |e 140000PD1232736317 |k 0/140000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1950302644 |e 4861448433 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapyPharmaceuticals","name":{"displayForm":["Molecular Diversity Preservation International"]},"pubHistory":["1.2004 -"],"recId":"491437528","note":["Gesehen am 05.09.2011"],"origin":[{"dateIssuedDisp":"2004-","publisherPlace":"Basel","publisher":"MDPI","dateIssuedKey":"2004"}],"id":{"zdb":["2193542-7"],"issn":["1424-8247"],"eki":["491437528"]},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Pharmaceuticals","title":"Pharmaceuticals"}],"part":{"pages":"1-28","text":"18(2025), 11, Artikel-ID 1670, Seite 1-28","volume":"18","issue":"11","year":"2025","extent":"28"}}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1950302644"],"doi":["10.3390/ph18111670"]},"note":["Im Titel sind ny und 3 tiefgestellt, der Ausdruck \"198Au\" steht in eckiger Klammer, 198 ist dabei hochgestellt","Gesehen am 27.01.2026"],"recId":"1950302644","name":{"displayForm":["Güllü Davarci, Carmen Wängler, Klaus Eberhardt, Margaret Tulessin, Christopher Geppert, Ralf Schirrmacher, Gert Fricker, Carolin Mogler, Marc Pretze and Björn Wängler"]},"titleAlt":[{"title":"Preclinical evaluation of stable integrin alpha nu beta 3 -specific (198 Au) gold nanoparticles for tumor therapy"}],"person":[{"role":"aut","given":"Güllü","display":"Davarci, Güllü","family":"Davarci"},{"given":"Carmen","display":"Wängler, Carmen","family":"Wängler","role":"aut"},{"role":"aut","given":"Klaus","display":"Eberhardt, Klaus","family":"Eberhardt"},{"given":"Margaret","family":"Tulessin","display":"Tulessin, Margaret","role":"aut"},{"display":"Geppert, Christopher","family":"Geppert","given":"Christopher","role":"aut"},{"given":"Ralf","family":"Schirrmacher","display":"Schirrmacher, Ralf","role":"aut"},{"role":"aut","given":"Gert","display":"Fricker, Gert","family":"Fricker"},{"given":"Carolin","family":"Mogler","display":"Mogler, Carolin","role":"aut"},{"given":"Marc","display":"Pretze, Marc","family":"Pretze","role":"aut"},{"role":"aut","display":"Wängler, Björn","family":"Wängler","given":"Björn"}],"physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"28 S."}],"title":[{"title_sort":"Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy","title":"Preclinical evaluation of stable integrin αvβ3-specific (198Au)gold nanoparticles for tumor therapy"}],"origin":[{"dateIssuedDisp":"4 November 2025","dateIssuedKey":"2025"}]} | ||
| SRT | |a DAVARCIGUEPRECLINICA4202 | ||